You are now leaving the Hypermunes.com Web site.

Links to external, non-Talecris Biotherapeutics Internet sites are provided as a courtesy; however, Talecris Biotherapeutics is not responsible for the availability or the content of such Web sites.

Please see our General Conditions of Use for more information.

OK     CANCEL
 

HyperTET® S/D [Tetanus Immune Globulin (Human)]
postexposure prophylaxis for tetanus

HyperTET® S/D Postexposure Prophylaxis for Tetanus

According to the Centers for Disease Control and Prevention (CDC), tetanus leads to death in about 1 in 10 cases.1 For more information, recommendations, and guidelines, visit the CDC—Advisory Committee on Immunization Practices (ACIP).

Immunization status may be unknown…but the level of protection shouldn’t be.

Imminent Threat

Vaccines can take weeks to build efficacy, which can protect for years. HyperTET S/D, along with wound cleaning and debridement, provides immediate protection. This allows the vaccine the time needed to establish active immunity for your patients in high-risk situations, such as2-6:

  • Those whose immunization status is unknown
    • Immigrants and visitors from other countries where tetanus toxoid vaccination is not mandatory
    • Patients who were born prior to vaccination series being mandatory
  • Patients with common injuries that can carry a risk of tetanus (eg, puncture wounds or soil contamination of open cuts)
  • Intravenous (IV) drug users

Hypermunes Vaccine Visual Aid

Immediate Protection

HyperTET S/D contains high titers of tetanus antibodies for postexposure prophylaxis, providing rapid immune protection for up to 21 days. According to the CDC, the use of a tetanus immune globulin such as HyperTET S/D may, if promptly administered, reduce the potentially life-threatening risk of tetanus when administered concomitantly with the tetanus vaccine.2,7,8

HyperTET S/D IMPORTANT SAFETY INFORMATION

HyperTET S/D should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immunoglobulin preparations. In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, HyperTET S/D should be given only if the expected benefits outweigh the risks.

Slight soreness at the site of injection and slight temperature elevation may be noted at times. Sensitization to repeated injections of human immunoglobulin is extremely rare. In the course of routine injections of large numbers of persons with immunoglobulin, there have been a few isolated occurrences of angioneurotic edema, nephrotic syndrome, and anaphylactic shock after injection.

Administration of live virus vaccines (eg, MMR) should be deferred for approximately 3 months after Tetanus Immune Globulin (Human) administration.

HyperTET S/D is made from human plasma. As with all plasma-derived therapeutics, the potential to transmit infectious agents, such as viruses and theoretically, the Creutzfeldt-Jakob (CJD) agent that can cause disease, cannot be totally eliminated. There is also the possibility that unknown infectious agents may be present in such products.

For full Prescribing Information, click here.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

References:

  1. Centers for Disease Control and Prevention. Vaccines and preventable diseases: Tetanus (lockjaw) vaccination. http://www.cdc.gov/vaccines/vpd-vac/tetanus/default.htm. Accessed June 15, 2009.

  2. Centers for Disease Control and Prevention. VPD surveillance manual, 4th edition, 2008.

  3. Talan DA, Abrahamian FM, Moran GJ, et al. Tetanus immunity and physician compliance with tetanus prophylaxis practices among emergency department patients presenting with wounds. Ann Emerg Med. 2004;43:305-314.

  4. Centers for Disease Control and Prevention. Tetanus. http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/tetanus-508.pdf. Accessed May 14, 2009.

  5. Baxter D. Active and passive immunity, vaccine types, excipients and licensing. Occupational Medicine. 2007;57:552-556.

  6. World Health Organization. Prevention and management of wound infection. http://www.who.int/entitiy/hac/techguidance/tools/Prevention%20and%20management%20of%20wound%20infection.pdf. Accessed June 15, 2009.

  7. Centers for Disease Control and Prevention. Principles of vaccination. http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/prinvac-508.pdf. Accessed June 15, 2009.

  8. HyperTET S/D [package insert]. Research Triangle Park, NC: Talecris Biotherapeutics; 2008.